 The choice of the best antiangiogenic agent in alternative to bevacizumab needs to be assessed. Small molecular inhibitor of tyrosine-protein-kinases TK could be used with efficacy after a first-line of antiangiogenesis treatment as it was demonstrated in renal cancer Escudier, 2011. 